ANGO at a glance
ANGIODYNAMICS INC (ANGO, SEC CIK 1275187) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on October 8, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended May 31, 2026 (FY2026), ANGIODYNAMICS INC (ANGO) reported revenue of $320.2 million (up 9.5% from FY2025) and a net loss of $36.7 million. Diluted EPS was -$0.88.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding ANGIODYNAMICS INC (ANGO) shares worth $217.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Trowbridge Stephen A on October 29, 2026 of 23,615 shares at $12.27 per share.
- In the last 90 days, ANGO insiders reported 0 open-market purchases ($0) and 2 open-market sales ($311K) on Form 4, a net sale of $311K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $320.2M
- +9.5% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$311K
- 13F holders
- 29 funds
- $217.7M · +1 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 5.02 · Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended May 31, 2026
Business Overview
- Core business model: design, manufacture, and sale of innovative medical devices for cardiovascular disease and cancer treatment
- New product emphasis: expanded FDA clearance for NanoKnife System prostate tissue ablation in Dec 2024 and MDR CE mark in Feb 2026 for multiple tumor ablations
- Strategic shift: divestiture of dialysis, BioSentry (June 2023), and PICC/Midline businesses (Feb 2024); discontinuation of RadioFrequency Ablation and Syntrax lines
- Quantitative metric: workforce reduced to approximately 632 full-time employees as of May 31, 2026
- Noteworthy fact: ongoing regulatory challenges delaying FDA clearances amid increased testing requirements and expanded MDR compliance through 2027-2028
Risk Factors
- Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
- Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs
- Supply chain vulnerability: Transition of manufacturing to third-party sites in U.S., Costa Rica, Latvia, Italy, Israel, China by Q1 FY2027 with risk of disruptions and increased costs
- Competitive risk: Price competition intensified by growing purchasing power of GPOs and IDNs, risking contract losses and reduced profitability
- Financial risk: CEO transition planned by Nov 2026 poses leadership uncertainty potentially impacting operations and investor confidence
Management Discussion & Analysis
- Revenue $320.2M, up 9.5% YoY ($292.5M in FY 2025); Med Tech grew 18.4% ($150.0M) strongest, Med Device up 2.6% ($170.2M)
- Gross margin 54.6% vs 53.9% YoY; Med Tech margin 63.6% vs 62.0%, Med Device margin declined 46.7% vs 47.7%
- Net loss increased to $36.7M from $34.0M; loss per share widened to $0.88 from $0.83
- Operating cash flow positive $3.1M vs negative $10.1M prior year; capex $2.6M plus $3.4M on unit placements; $1.7M stock buybacks in FY 2025, none in FY 2026
- Management pursuing restructuring to save $15M annually by FY 2027; share repurchase authorization $15M with $13.3M remaining; key risks include inflation, tariffs, supply chain disruptions
AI summary of the ANGO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Aug 31, 2026
Management Discussion & Analysis
- Revenue $80.9M, up $5.2M or 6.9% YoY from $75.7M
- Gross margin 59.4% vs 55.3% YoY, Med Tech margin 66.2% vs 62.2%
- Med Tech strongest, revenue up 13.2% to $39.9M; Med Device weakest, up 1.4% to $41.0M
- Cash $34.0M vs $53.9M at May 31; operating cash use $15.3M, Auryon placements $2.8M
- Headwinds: inflation, tariffs, labor shortages, supply-chain challenges, backlog; liquidity sufficient for at least 12 months
Risk Factors
- No material changes to fiscal 2026 10-K risk factors
- Legal risk: approximately [number obscured] port product-liability claims remain pending
- Regulatory risk: FDA actions or changing medical-device regulations could delay product clearances or approvals
- Operational risk: manufacturing, supply-chain, labor, inflation and tariff pressures could disrupt production and margins
- Financial risk: cash declined to $34.0 million after $15.3 million operating cash outflow; no revolving debt outstanding
- Currency risk: 2.3% of sales denominated in foreign currencies, with no comparable foreign-currency expenses
AI summary of the ANGO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved an amended 2020 Equity Incentive Plan on November 17, 2026
- Increased share authorization supports future employee and executive equity awards
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual meeting completed November 17, 2026, with both Class II nominees elected through the 2029 annual meeting
- Eileen O. Auen received 28,252,245 votes for, while Jan Stern Reed received 27,956,254
Item EX-99.1: Item EX-99.1
- Eric Honroth appointed President, CEO, and director effective November 2, 2026
- Jim Clemmer retiring after 10 years as CEO, leaving the Board but continuing as a transition consultant
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO transition effective November 2, 2026: Eric Honroth succeeds James Clemmer after Clemmer’s retirement
- Honroth brings Getinge, Abbott Vascular, Becton Dickinson, CareFusion and Boston Scientific leadership experience
Item 1.01: Entry into a Material Definitive Agreement
- Eric Honroth appointed President and Chief Executive Officer under employment agreement dated October 3, 2026
- Leadership transition creates potential strategic and operational impact for AngioDynamics
Item EX-99.2: Item EX-99.2
- Q1 FY2027 revenue $80.9M, up 6.9% year over year, with Med Tech up 13.2% and Med Device up 1.4%
- Med Tech momentum led by NanoKnife up 29.0%, Auryon up 14.7%, and AlphaVac up 37.4%
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $80.9M, up 6.9%, with Med Tech growth 13.2% offsetting largely flat Med Device sales
- Adjusted EBITDA rose to $5.0M from $2.2M, while adjusted loss narrowed to $0.04 per share from $0.10
Item 7.01: Regulation FD Disclosure
- Presentation slides cover AngioDynamics’ fiscal first quarter ended August 31, 2026
- Exhibit 99.2 likely contains quarterly operating results, management commentary and outlook
Item 2.02: Results of Operations and Financial Condition
- Press release covers fiscal Q1 ended August 31, 2026
- Financial results and management commentary available in Exhibit 99.1
AI summaries of ANGO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANGO
Don't miss the next ANGO filing
- Alerts as it files. A push when ANGO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANGO, by share count.
- Ask anything. An AI agent that reads every ANGO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Honroth Eric | A | Nov 2, 2026 | 62,928 | - |
| Honroth Eric | A | Nov 2, 2026 | 38,265 | - |
| Honroth Eric | A | Nov 2, 2026 | 62,928 | - |
| Trowbridge Stephen A | Sell | Oct 29, 2026 | 23,615 | $12.27 |
| Trowbridge Stephen A | Sell | Oct 28, 2026 | 1,720 | $12.17 |
| Nighan Warren JR | Sell | Jul 30, 2026 | 23,370 | $14.72 |
| Piccinini Laura | M | Jul 22, 2026 | 8,047 | - |
| Piccinini Laura | F | Jul 22, 2026 | 4,506 | $13.82 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $292.5M | $320.2M |
| Gross Profit | - | $157.7M | $174.9M |
| Operating Income | - | -$40.0M | -$39.9M |
| Net Income | - | -$34.0M | -$36.7M |
| Gross Margin | - | 53.9% | 54.6% |
| Op. Margin | - | -13.7% | -12.5% |
| Net Margin | - | -11.6% | -11.5% |
| Balance Sheet | |||
| Total Assets | $317.7M | $280.1M | $267.2M |
| Equity | $205.6M | $183.0M | $170.8M |
| ROE | - | -18.6% | -21.5% |
| Per Share | |||
| EPS | - | $-0.83 | $-0.88 |
| Cash Flow | |||
| Operating CF | - | -$10.1M | $3.1M |
| CapEx | - | $4.5M | $2.6M |
Source: XBRL data in ANGIODYNAMICS INC (ANGO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ANGO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $217.7M |
| Q2 2026 | 28 | $162.2M |
| Q1 2026 | 28 | $138.1M |
| Q4 2025 | 26 | $160.3M |
| Q3 2025 | 27 | $143.2M |
| Q2 2025 | 29 | $127.2M |
| Q1 2025 | 25 | $91.7M |
| Q4 2024 | 22 | $96.2M |
- Two Sigma Investments+970.7K (+317%)
- Goldman Sachs Group+324.4K (+85%)
- BlackRock+245.7K (+6%)
- Morgan Stanley+136.9K (+53%)
- AQR Capital Management+90.4K (+15%)
- Millennium Management−260.9K (-33%)
- Bank of America Corp−171.0K (-50%)
- Renaissance Technologies LLC−113.5K (-15%)
- Wells Fargo & Co−20.4K (-58%)
- Dimensional Fund Advisors−20.2K (-2%)
- D.E. Shaw & Co+185.3K
- Raymond James Financial+16.1K
- FMR LLC (Fidelity)−104.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANGO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 10-Q | Oct 8, 2026 | Aug 31, 2026 | Analysis | |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ANGO SEC filings: frequently asked questions
Are ANGO insiders buying or selling?
In the last 90 days, ANGIODYNAMICS INC (ANGO) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $310,688 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANGO stock?
As of September 30, 2026, the largest ANGIODYNAMICS INC (ANGO) holders among the 13F filers tracked by SignalX were BlackRock ($62.3 million), Vanguard Capital Management LLC ($26.3 million), Two Sigma Investments ($19.6 million), State Street Corp ($15.2 million), Dimensional Fund Advisors ($14.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANGO's revenue in fiscal year 2026?
For the fiscal year ended May 31, 2026 (FY2026), ANGIODYNAMICS INC (ANGO) reported revenue of $320.2 million (up 9.5% from FY2025) and a net loss of $36.7 million. Diluted EPS was -$0.88. The figures come from the XBRL data in the 10-K.
What are the main risks in ANGO's latest 10-K?
In the 10-K filed July 14, 2026, ANGIODYNAMICS INC (ANGO) flagged: Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act. Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs. (AI summary of the Risk Factors section.)
What did ANGO report in its latest 8-K?
ANGIODYNAMICS INC (ANGO) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved an amended 2020 Equity Incentive Plan on November 17, 2026.
What are the latest ANGO SEC filings?
ANGIODYNAMICS INC (ANGO) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on October 8, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 4, 2026.
What is ANGO's SEC CIK number?
ANGIODYNAMICS INC (ANGO)'s SEC Central Index Key (CIK) is 1275187. EDGAR lists every ANGO filing under that number.
Ask anything about ANGO
The research agent reads ANGO's filings, financials, insider trades and 13F holders, then answers with sources.